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Abstract: Marine microorganisms possess unique metabolic and physiological features and are
an important source of new biomolecules, such as biosurfactants. Some of these surface-active
compounds synthesized by marine microorganisms exhibit antimicrobial, anti-adhesive and
anti-biofilm activity against a broad spectrum of human pathogens (including multi-drug resistant
pathogens), and could be used instead of existing drugs to treat infections caused by them. In other
cases, these biosurfactants show anti-cancer activity, which could be envisaged as an alternative to
conventional therapies. However, marine biosurfactants have not been widely explored, mainly
due to the difficulties associated with the isolation and growth of their producing microorganisms.
Culture-independent techniques (metagenomics) constitute a promising approach to study the genetic
resources of otherwise inaccessible marine microorganisms without the requirement of culturing
them, and can contribute to the discovery of novel biosurfactants with significant biological activities.
This paper reviews the most relevant biosurfactants produced by marine microorganisms with
potential therapeutic applications and discusses future perspectives and opportunities to discover
novel molecules from marine environments.
Keywords: biosurfactant; antimicrobial activity; anti-adhesive activity; anti-biofilm activity;
anti-cancer activity; metagenomics
1. Introduction
A huge and extensive source of natural compounds can be retrieved from the marine
environment [1,2]. Marine microorganisms exhibit unique metabolic and physiological capabilities
conferring them the ability to survive in extreme conditions and consequently produce novel
metabolites that cannot be found elsewhere [3,4]. Hence, the marine environment holds a great
promise towards the discovery of novel bioactive and relevant compounds including antibiotics,
enzymes, vitamins, drugs and biosurfactants, among others [1,5,6].
Biosurfactants have attracted much attention in recent years; they are surface-active compounds
synthesized by microorganisms that exhibit diverse chemical structures, including glycolipids,
lipopeptides, polysaccharide-protein complexes, phospholipids, fatty acids and neutral lipids [4,5,7].
Due to their amphipathic nature, biosurfactants display a variety of surface activities, which allows
their application in several fields related with emulsification, foaming, detergency, wetting, dispersion
and solubilisation of hydrophobic compounds [8,9]. Many biosurfactants have been reported to possess
a similar or better performance when compared with synthetic surfactants, which in addition to their
lower toxicity, higher biodegradability and effectiveness at extreme temperatures, salinities and pH
values, make them a green alternative to their chemical counterparts in different applications, including
agriculture, food, cosmetics or petroleum industries, as well as in bioremediation [8–12]. Furthermore,
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several biosurfactants exhibit antibacterial, antifungal, antiviral or anti-tumour activities, making them
potential alternatives to conventional therapeutic agents in many biomedical applications [4,7–9,13].
Biosurfactant-producing microorganisms are ubiquitous, inhabiting both water (sea, fresh water
and ground water) and land (soil, sediment and sludge), as well as environments characterized by
extreme conditions of pH, temperature or salinity (e.g., hyper saline sites and oil reservoirs) [4,14–17].
Due to their unique environmental conditions, the marine environments are a good source for
the isolation of new biosurfactant-producing microorganisms. A considerable number of marine
microorganisms able to produce biosurfactants with different structures have been reported,
as discussed below. However, it has to be taken into account that the great majority of the
marine microbial diversity remains unexplored, mainly due to the difficulty of growing marine
microorganisms under laboratory conditions [6,18–20].
This paper reviews the most relevant biosurfactants produced by marine microorganisms with
potential therapeutic applications, and discusses future perspectives and opportunities to discover
novel biosurfactants from marine environments.
2. Biosurfactants from Marine Microorganisms: New Weapons to Fight Human Pathogens
Most human bacterial infections can be successfully treated using current antibiotic therapies.
However, in recent years, a significant increase in the emergence of pathogenic microorganisms
resistant to the available antimicrobials has been observed, including multi-drug resistant (MDR)
pathogens, which has been associated with the misuse or abuse of antibiotics. As a result, persistent and
difficult to treat infectious diseases appeared, which constitutes a serious public health problem [21].
Furthermore, in the last decades, the discovery of new antimicrobials has declined considerably
(only two new classes of antibiotics have been commercialized since 1962), due to the difficulties in
identifying novel and effective compounds and the subsequent high economic investments required
for their development [21]. Therefore, there is an urgent demand for novel antimicrobial drugs.
Several biosurfactants have been reported to exhibit antimicrobial activity against different human
pathogens; furthermore, these compounds usually display anti-adhesive and anti-biofilm activities,
making them useful to reduce the adhesion and colonization by pathogenic microorganisms, as well as
to remove pre-formed biofilms [22–25]. Although biosurfactants have been extensively studied, most
of them were obtained from microorganisms isolated from terrestrial samples or hydrocarbon-polluted
areas, whereas biosurfactants produced by marine microorganisms have been less explored [26].
The most relevant biosurfactants produced by marine microorganisms exhibiting antimicrobial,
anti-adhesive or anti-biofilm activities against different pathogenic and opportunistic microorganisms
are shown in Table 1. Several of these biosurfactants are effective against a broad spectrum of human
pathogens, including Gram-positive and Gram-negative bacteria, as well as the yeast Candida albicans.
Furthermore, in some cases they are also effective against MDR clinical isolates. Therefore, they can be
an alternative to the existing drugs to treat infections caused by those pathogens.
It should be noted that, with the exception of the isolate Serratia marcescens described by Dusane
and co-workers [28], all the other microorganisms reported in Table 1 were isolated from marine
samples collected in the coastal waters of India, which suggests a higher investment of this country
in the exploration of the marine resources. Regarding the phylogeny of the different isolates, more
than half of them are actinomycetes. Furthermore, most of those microorganisms were isolated from
marine macro-organisms. Marine sponges and other marine invertebrates are important sources of
novel bioactive compounds, including antimicrobial, anti-adhesive and anti-biofilm agents. These
compounds play a critical role in their defence against predators, infectious agents and biofilm-forming
microorganisms, and most of them are synthesized by symbiotic microorganisms and not by the host
macro-organism [28,31,37,38].
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Table 1. Biosurfactants produced by marine microorganisms with antimicrobial, anti-adhesive or anti-biofilm activities against human pathogens.
Microorganism (Origin) Biosurfactant Type (Structure) Activity Reference
Brevibacterium casei MSA19 (marine
sponge Dendrilla nigra) Glycolipid (unknown)
Antimicrobial activity against Escherichia coli, Klebsiella pneumoniae,
Proteus mirabilis, Pseudomonas aeruginosa, haemolytic Streptococcus,
Vibrio parahaemolyticus and Vibrio vulnificus
[27]
Anti-biofilm activity against mixed and individual cultures of E. coli,
P. aeruginosa and Vibrio spp.
Serratia marcescens (hard marine coral
Symphyllia sp.) Glycolipid (glucose + palmitic acid)
Antimicrobial, anti-adhesive and anti-biofilm activity against
Candida albicans and P. aeruginosa [28]
Streptomyces sp. B3 (marine
sediment samples) Glycolipid (unknown)
Antimicrobial activity against C. albicans, E. coli, P. aeruginosa and
Staphylococcus aureus [29]
Streptomyces sp. MAB36 (marine
sediment samples) Glycolipid (unknown)
Antimicrobial activity against Aspergillus niger, Bacillus cereus, C. albicans,
Enterococcus faecalis, Shigella boydii, Shigella dysenteriae and S. aureus [30]
Aspergillus ustus MSF3 (marine
sponge Fasciospongia cavernosa) Glycolipoprotein (unknown)
Antimicrobial activity against C. albicans, E. faecalis, E. coli, K. pneumoniae,
Micrococcus luteus, P. mirabilis, P. aeruginosa, S. aureus, Staphylococcus
epidermidis and haemolytic Streptococcus
[31]
Bacillus circulans (seawater sample) Lipopeptide (unknown)
Antimicrobial activity against Acinetobacter calcoaceticus, Citrobacter freundii,
Enterobacter cloacae, E. coli, Micrococcus luteus, P. mirabilis, Proteus vulgaris,
Serratia marcescens and multi-drug resistant E. coli a, K. pneumoniae b and
S. aureus c [32,33]
Anti-adhesive and anti-biofilm activities against C. freundii, E. coli, P. vulgaris,
Salmonella typhimurium and S. marcescens
Bacillus circulans DMS-2
(marine samples)
Lipopeptide (Mixture of three different Fengycins: β-hydroxy
fatty acid of 15, 16 or 17 carbons + cyclic decapeptide) Antimicrobial activity against C. freundii, E. coli, P. vulgaris and S. marcescens [34]
Bacillus licheniformis NIOT-AMKV06
(marine sponge Acanthella sp.) Lipopeptide (unknown)
Antimicrobial activity against E. faecalis, K. pneumoniae, M. luteus, P. mirabilis,
Salmonella typhi, Shigella flexineri, S. aureus and Vibrio cholera [35]
Brevibacterium aureum MSA13
(marine sponge Dendrilla nigra)
Lipopeptide (Brevifactin: Octadecanoic acid methyl
ester + pro-leu-gly-gly)
Antimicrobial activity against C. albicans, E. coli, K. pneumoniae, M. luteus,
P. mirabilis, P. aeruginosa, S. aureus, S. epidermidis and haemolytic Streptococcus [36]
Nocardiopsis alba MSA10 (marine
sponge Fasciospongia cavernosa) Lipopeptide (unknown)
Antimicrobial activity against C. albicans, E. faecalis, K. pneumoniae, M. luteus,
P. mirabilis, S. aureus and S. epidermidis [37]
Nocardiopsis dassonvillei MAD08
(marine sponge Dendrilla nigra) Unknown
Antimicrobial activity against S. aureus, M. luteus and multi-drug resistant
E. coli d, K. pneumoniae d, P. mirabilis d, P. aeruginosa d, S. typhi d,
S. epidermidis d, non-haemolytic Streptococcus d and V. cholera d
[38]
a resistant to ciprofloxacin, ofloxacin, levofloxacin, streptomycin, penicillin, ceftazidine, norfloxacin and ofloxacin; b resistant to ceftriaxone, ciprofloxacin, ofloxacin, levofloxacin,
norfloxacin, piperacillin, tazobactam, streptomycin and penicillin; c resistant to methicillin and streptomycin; d resistant to chloramphenicol, streptomycin, oxytetracycline, ampicillin
and erythromycin.
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In most of the above referred studies, the biosurfactants were only partially characterized and their
activities were studied using the crude extracts rather than purified molecules. However, in other cases
a more complete chemical characterization was performed. Regarding the lipopeptide biosurfactant
produced by the Bacillus circulans strain reported by Das et al. [32], six different fractions were obtained
from the crude extract using reverse phase HPLC, and only one of them was responsible for the
antimicrobial activity exhibited by the crude biosurfactant. It should be pointed out that, contrary to
other lipopeptide biosurfactants such as surfactin, this biosurfactant did not show haemolytic activity,
which could facilitate its use as a therapeutic agent [32]. Similarly, the lipopeptide biosurfactant
produced by B. circulans DMS-2 was identified as a mixture of different fengycin isoforms (including
C15-, C16- and C17-fengycin). Four different surface-active fractions were resolved and purified through
HPLC, and only one of them (containing C16- and C17-fengycin) was responsible for the antimicrobial
activity observed in the crude biosurfactant [34].
Additionally, several biosurfactants reported in Table 1 displayed a similar or better performance
when compared with conventional antibiotics. In order to compare the antimicrobial activity exhibited
by different compounds, the minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC) are commonly used parameters. The MIC for an antimicrobial compound against
a specific microorganism is the minimum concentration of that compound that completely inhibits the
growth of that microorganism. The MBC is the minimum concentration of that compound that is lethal
for that microorganism. One of the HPLC-purified fractions of the lipopeptide biosurfactant produced
by B. circulans showed lower MICs and MBCs against S. marcescens, Proteus vulgaris and Enterobacter
cloacae (between 10 and 60 µg¨ mL´1) when compared with the conventional antibiotics penicillin and
streptomycin (between 40 and 900 µg¨ mL´1). Regarding the MDR Escherichia coli, Klebsiella pneumoniae
and Staphylococcus aureus (which were resistant to penicillin and streptomycin at concentrations up to
1000 µg¨ mL´1), MICs and MBCs between 60 and 800 µg¨ mL´1 and 200–1000 µg¨ mL´1, respectively,
were obtained for this biosurfactant [32]. The glycolipid biosurfactant produced by Streptomyces
sp. MAB36 possessed a similar inhibitory activity against Aspergillus niger and C. albicans to the
conventional antifungal nystatin [30]. The biosurfactant produced by Nocardiopsis dassonvillei MAD08
was more effective against E. coli and Staphylococcus epidermidis than chloramphenicol [38]. Finally, the
biosurfactant produced by S. marcescens exhibited a higher inhibitory effect against C. albicans and
Pseudomonas aeruginosa as compared to the conventional antimicrobials fluconazole and streptomycin,
respectively [28].
In addition, some of these biosurfactants displayed a considerable anti-adhesive and anti-biofilm
activity. The biosurfactant produced by B. circulans (partially purified through gel filtration
chromatography) exhibited anti-adhesive activity at concentrations between 0.1 and 10 mg¨ mL´1.
At the highest concentration tested (10 mg¨ mL´1), microbial adhesion was inhibited between 84%
and 89%, and pre-formed biofilms were removed (with efficiencies between 59% and 94%) for all the
pathogenic microorganisms tested [33]. The glycolipid biosurfactant produced by Brevibacterium casei
MSA19 (partially purified through thin layer chromatography) removed pre-formed biofilms of all the
pathogenic microorganisms tested at 30 µg¨ mL´1 [27].
Despite their potential applications, the widespread use of biosurfactants is still limited by their
low productivities. The optimization of the culture medium and cultivation conditions can greatly
contribute to increase their production yields [31,37]. Furthermore, the composition of the culture
medium can alter the structure and activity of the biosurfactant. In the case of the isolate B. circulans,
the antimicrobial activity of the biosurfactant was dependent on the carbon source used, due to the
production of different isoforms in the different media; the biosurfactant produced using culture media
containing glycerol, starch or sucrose exhibited a higher antimicrobial activity when compared with the
one produced in a medium containing glucose [39]. However, in the case of marine microorganisms,
which are adapted to the marine environment conditions, their cultivation in the laboratory or in
industrial fermenters can be difficult. One alternative is to produce those biosurfactants in heterologous
hosts. In the case of the lipopeptide biosurfactant produced by Bacillus licheniformis NIOT-AMKV06,
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three genes involved in its biosynthesis (sfp, sfpO, and srfA) were cloned and expressed in E. coli.
As a result, biosurfactant production was increased from 3 g¨ L´1 up to 11.7 g¨ L´1 [35].
Although not included in Table 1, the strain Streptomyces sp. ISP2-49E, isolated from marine
sediment samples obtained from Galveston Bay (Texas) must be mentioned. This isolate produced
the rhamnolipid biosurfactant L-rhamnosyl-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate
(Rha-Rha-C10-C10), being the first report on a rhamnolipid-producing Streptomyces strain [15]. Although
the properties of the biosurfactant synthesized by this isolate were not studied in detail, rhamnolipids
have been reported to possess a broad spectrum of antimicrobial and anti-adhesive activities [22,23].
However, the main rhamnolipid producers are P. aeruginosa strains, an opportunistic human pathogen.
Therefore, the use of alternative non-pathogenic rhamnolipid producers can contribute to the safe
use of rhamnolipids as therapeutic agents. That can be achieved using either non-pathogenic natural
rhamnolipid-producing strains [15,40–42], or engineered non-pathogenic hosts expressing the genes
required for the synthesis of rhamnolipids [43,44].
The antagonistic activities exhibited by these biosurfactants against human pathogens (including
MDR pathogens) make them candidates to be used as an alternative to traditional antibiotics. However,
despite their great potential, none of these compounds is yet being used for the treatment of
human infections.
3. Biosurfactants from Marine Microorganisms: Alternative Anti-Cancer Agents
Cancer represents an extremely important health risk affecting millions of people worldwide [45];
hence, any progress leading to enhanced survival is a global priority. Given its unpredictable nature,
cancer is a major concern for human health. Several strategies have been pursued over the years,
whether searching for new biomarkers, treatments or drugs. However, despite these efforts, a successful
targeted selective and non-toxic therapy is still to be developed. Traditional cancer chemotherapy
has mainly been based on using highly cytotoxic drugs that non-specifically target any dividing
cells; this may result in a modest improvement in patient survival, thus overall prognosis of most
patients remains dismal and treatment is non-specific, non-selective and toxic. In this sense, the
search and development of new anti-cancer drugs that can overcome the multi-drug resistance of
cancer cells remains a great challenge. Currently, many anti-cancer drugs used in clinical practice are
natural products or derivatives thereof [46–49]. For that reason, it is likely that the continued and
systematic exploration of natural sources, such as the marine microbiota, will lead to different and
unforeseen compounds with interesting biological activities, including anti-cancer activity [50,51]. The
microbial production of anti-cancer drugs is advantageous compared to their extraction from natural
sources such as plants, namely the possibility of genetically engineering microbes for a given purpose,
as well as their higher production rates [52]. As previously mentioned, biosurfactants are among those
microbial compounds exhibiting promising biological activities [53].
Biosurfactants, in particular lipopeptides and glycolipids, have been highlighted for their potential
to be used as anti-cancer agents interfering with cancer progression processes (Figure 1) [7]. These
compounds have been implicated in several intercellular molecular recognition steps comprising signal
transduction, cell differentiation and cell immune response, among others [24]. In addition, they exhibit
low toxicity, high efficacy and easy biodegradability, which are relevant features in any anti-cancer
agent. Different mechanisms underlying the anti-cancer activity of biosurfactants have been proposed
including the delay of cell cycle progression; inhibition of crucial signalling pathways such as Akt,
extracellular signal-regulated kinase/c-Jun N-terminal kinase (ERK/JNK) and Janus kinase/signal
transducer and activator of transcription (JAK/STAT); reduction of angiogenesis; activation of natural
killer T (NKT) cells; and induction of apoptosis through death receptors in cancer cells. In addition,
the ability of biosurfactants to disrupt cell membranes, leading to a sequence of events that include
lysis, increased membrane permeability and metabolite leakage, has also been pointed as a probable
mechanism of anti-cancer activity [54].
Mar. Drugs 2016, 14, 38 6 of 15
Mar. Drugs 2016, 14, x 7 of 16 
 
signalling pathways such as Akt, extracellular signal-regulated kinase/c-Jun N-terminal kinase 
(ERK/JNK) and Janus kinase/signal transducer and activator of transcription (JAK/STAT); reduction 
of angiogenesis; activation of natural killer T (NKT) cells; and induction of apoptosis through death 
receptors in cancer cells. In addition, the ability of biosurfactants to disrupt cell membranes, leading 
to a sequence of events that include lysis, increased membrane permeability and metabolite leakage, 
has also been pointed as a probable mechanism of anti-cancer activity [54]. 
Despite this exciting potential and the great diversity of chemical structures that can be found 
among biosurfactants, the majority of the studies on their anti-cancer activity have been conducted 
with few well-known molecules produced by microbes mainly isolated from terrestrial sources. 
Therefore, other natural environments, such as the marine microbiota, open up a great opportunity 
to discover new biosurfactants exhibiting distinct chemical structures and powerful anti-cancer 
activities provided by different mechanisms of action and/or different targets. 
 
Figure 1. Properties and anti-cancer effects of biosurfactants towards the design of novel  
cancer therapies. 
Lipopeptides, particularly surfactin, have been widely studied for their potential anti-cancer 
activity against a number of cancer cell lines [7,53,55]. The anti-cancer activity of surfactin has been 
related with the hydrophobic nature of the fatty acid moiety that interacts with the acyl chain of 
membrane-bound phospholipids [56]. Simultaneously, its peptide moiety strongly interacts with the 
polar heads of the membrane lipids in cancer cells. Surfactin, holding a longer fatty acid chain, 
penetrates more efficiently into the cancer cell membrane [56]. Different mechanisms have been 
suggested for its anti-cancer activity depending on the cancer models evaluated (breast, colon, 
leukaemia, hepatic, melanoma) [7] including the inhibition of matrix metalloproteinases (protease 
enzymes involved in invasion and metastasis processes) [57]; PI3/Akt and MAPK signalling 
pathways [56]; cell cycle arrest at G2/M [58]; and induction of apoptosis via ROS/JNK-mediated 
mitochondrial/caspase pathway [59]. This cyclic lipopeptide comprised by seven amino acids and a 
lipid moiety (containing 13 to 15 carbons) is produced by several strains of bacilli retrieved from 
different sources, including the marine environment [7,53,60]. The marine bacterium B. circulans 
DMS-2 was found to produce lipopeptides, namely surfactin and fengycin isoforms, displaying a 
significant and selective anti-proliferative activity against the human colon cancer cell lines HCT-15 
(IC50 80 µg·mL−1) and HT-29 (IC50 120 µg·mL−1) [55]. 
In addition, different bacilli strains produce iturins (bacillomycins, iturin A/C and 
mycosubtilins). These lipopeptides are amphiphilic molecules containing a cyclic peptide chain 
conjugated with a β-amino fatty acid (containing 13 to 17 carbons). Iturin A, produced by a marine 
Bacillus megaterium strain, was found to significantly impair proliferation and inhibit the Akt 
signalling network leading to apoptosis induction in breast cancer cells (MDA-MB-231 and MCF-7). 
It is important to note that treatments that can inhibit breast cancer types exhibiting aberrant Akt 
activity are of utmost importance. Additionally, this biosurfactant inhibited EGF induced Akt 
phosphorylation and its downstream targets GSK3β and FoxO3α. Iturin A was also found to inhibit 
tumour growth in a breast cancer xenograft model [61]. Other biosurfactants produced by marine 
i r 1. Properties and anti-cancer e fects of i rf cta ts r s l
r t r i s.
Despite this exciting potential and the great diversity of chemical structures that can be found
among biosurfactants, the majority of the studies on their anti-cancer activity have been conducted with
few well-known molecules produced by microbes mainly isolated from terrestrial sources. Therefore,
other natural environments, such as the marine microbiota, open up a great opportunity to discover
new biosurfactants exhibiting distinct chemical structures and powerful anti-cancer activities provided
by different mechanisms of action and/or different targets.
Lipopeptides, particularly surfactin, have been widely studied for their potential anti-cancer
activity against a number of cancer cell lines [7,53,55]. The anti-cancer activity of surfactin has
been related with the hydrophobic nature of the fatty acid moiety that interacts with the acyl chain
of membrane-bound phospholipids [56]. Simultaneously, its peptide moiety strongly interacts
with the polar heads of the membrane lipids in cancer cells. Surfactin, holding a longer fatty
acid chain, penetrates more efficiently into the cancer cell membrane [56]. Different mechanisms
have been suggested for its anti-cancer activity depending on the cancer models evaluated (breast,
colon, leukaemia, hepatic, melanoma) [7] including the inhibition of matrix metalloproteinases
(protease enzymes involved in invasion and metastasis processes) [57]; PI3/Akt and MAPK signalling
pathways [56]; cell cycle arrest at G2/M [58]; and induction of apoptosis via ROS/JNK-mediated
mitochondrial/caspase pathway [59]. This cyclic lipopeptide comprised by seven amino acids and
a lipid moiety (containing 13 to 15 carbons) is produced by several strains of bacilli retrieved from
different sources, including the marine environment [7,53,60]. The marine bacterium B. circulans
DMS-2 was found to produce lipopeptides, namely surfactin and fengycin isoforms, displaying
a significant and selective anti-proliferative activity against the human colon cancer cell lines HCT-15
(IC50 80 µg¨ mL´1) and HT-29 (IC50 120 µg¨ mL´1) [55].
In addition, different bacilli strains produce iturins (bacillomycins, iturin A/C and mycosubtilins).
These lipopeptides are amphiphilic molecules containing a cyclic peptide chain conjugated with
a β-amino fatty acid (containing 13 to 17 carbons). Iturin A, produced by a marine Bacillus megaterium
strain, was found to significantly impair proliferation and inhibit the Akt signalling network leading
to apoptosis induction in breast cancer cells (MDA-MB-231 and MCF-7). It is important to note
that treatments that can inhibit breast cancer types exhibiting aberrant Akt activity are of utmost
importance. Additionally, this biosurfactant inhibited EGF induced Akt phosphorylation and its
downstream targets GSK3β and FoxO3α. Iturin A was also found to inhibit tumour growth in a breast
cancer xenograft model [61]. Other biosurfactants produced by marine microorganisms have been
reported among the iturin class, such as hallobacillin [62] and mixirins [63]. Hallobacillin, produced by
a Bacillus sp. isolated from marine sediments near the Guaymas Basin (Mexico), is cytotoxic against the
human colon cancer cell line HCT-116 (IC50 0.98 µg¨ mL´1) [63]. Mixirins (A, B and C), also isolated
from a marine Bacillus sp. strain, are cyclic octapeptides comprised by a mixture of L- and D-amino
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acid with an unusual β-amino alkanoic acid. Likewise, these lipopeptides were cytotoxic against colon
cancer cells, being the variant A the most potent [63].
It is clear that the marine environment represents a promising source of novel added value
compounds. Among these compounds, some new biosurfactant structures have been reported, namely
somocystinamide A [64], fellutamides [65–67], rakicidin [68–72] and apratoxin [73–77].
Wrasidlo and collaborators [78] obtained the lipopeptide somocystinamide A from the
cyanobacteria Lyngbya majuscula. This biosurfactant exhibited significant cytotoxicity against
leukaemia, lung, breast and prostate cancer cells with IC50 values ranging from 1.3 µM to 970 nM
depending on the cancer model. It is considered a pluripotent inhibitor of angiogenesis and tumour
cell proliferation. Moreover, it induced apoptosis in Jurkat and leukaemia cells through caspase-8
activation and PARP cleavage. Somocystinamide A was also found to effectively block endothelial
cell tube formation in vitro and blood vessel growth in a zebrafish model, thus suggesting its
anti-angiogenic character.
Fellutamides A and B are linear lipopeptides isolated from the fish-derived fungus
Penicillium fellutanum. These biosurfactants were found to be cytotoxic against P388, L1210 murine
leukaemia cells and KB human epidermoid carcinoma cells [67]. Fellutamides C and F, isolated from
the sponge-derived fungus Aspergillus versicolor, displayed cytotoxic effects against SK-MEL-2 skin
cancer, XF498 CNC cancer, HCT-15 colon cancer, A549 lung cancer and SK-OV-3 ovarian cancer cell
lines, with IC50 values ranging from 3.1 to 33.1 µM for fellutamide C, and between 0.2 and 3.1 µM for
fellutamide F [65,66].
Rakicidins are anti-cancer lipopeptides produced by the marine bacterium Micromonospora [69,70].
Among these lipopeptides, rakicidin A exhibits a unique hypoxia-selective cytotoxicity against several
cancer cell lines, such as HCT-8 and PANC-1 [72]. Hypoxia is present mainly in solid tumours and
is associated with a poor prognosis and clinical outcome since it triggers invasiveness, angiogenesis,
metastasis and apoptosis evasion [72]. Rakicidin B has also been reported to be active against
oesophageal squamous carcinoma cells (EC109), lung cancer cells (A549 and 95D), gastric cancer
cells (SGC7901), uterine cervix cancer cells (HeLa) and hepatocellular carcinoma cells (HepG2) [70].
This rakicidin derivative induced apoptosis through the activation of caspase-3, -7 and -9, and blocked
MAPK and JNK/p38 signalling pathways. Rakicidin derivatives C and D containing short lipid chains
were non cytotoxic [68], although the derivative D was found to interfere with the invasiveness of
aggressive breast cancer cells [68].
Apratoxins (derivatives A to G) are a new group of cyclic lipopeptides isolated from marine
cyanobacteria [74] that exhibit a significant cytotoxicity against a number of cancer cells. Apratoxin A
induced apoptosis through caspases activation and inhibited the IL-6 signalling pathway in human
bone osteosarcoma U2OS cells. Two apratoxin analogues (apratoxin A sulfoxide and apratoxin H)
isolated from the cyanobacterium Moorea producens showed a great cytotoxicity on human NCI-H460
lung cancer cells [76]. Other research groups also reported strong cytotoxicity against this cell line
using other apratoxin derivatives (D, F and G) [75]. Apratoxin E, F and G were also active against
HCT-116 colon cancer cells and in a mouse model [77].
Glycolipids have also been shown to be involved in growth arrest and apoptosis of several
cancer cells [7,79]. Some glycolipids obtained from marine sponges have been reported, such
as α-galacosylceramide (KRN7000) [80–83], myrmekioside or trikentroside [84]. KRN7000 is a
glycolipid containing a sugar moiety connected to a fatty acid chain and a sphingosine base that
exhibited anti-cancer activity against liver, lung, EL-4 lymphoma, colon 26 adenocarcinoma, EL-4T
cell lymphoma and sarcoma [80,82]. KRN7000 was shown to activate invariant natural killer T cells
and subsequent production of interferon (IFN)-g, IL-4 and other cytokines in a dose-dependent
manner [81]. Moreover, this glycolipid was found to have an inhibitory effect in advanced cancer
patients with hepatitis B or C infection [83]. Myrmekioside is a glycolipid produced by the marine
sponge Myrmekioderma dendyi. Its derivatives (E-1, E-2 and E-3) exhibited anti-cancer activity against
two human non-small-cell lung cancer cells (NSCLC-N6 and A549) [84]. The related glycolipid,
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trikentroside, isolated from the sponge Trikentrion, also inhibited the proliferation of human non-small
lung cancer A549 cells [84].
Many biosurfactant chemical structures and anti-cancer activities derived from the marine
environment are still to be discovered opening up fascinating opportunities of further developments
that certainly will benefit mankind.
4. New Perspectives for the Discovery of Novel Therapeutics
Oceans, which cover more than 70% of the Earth’s surface, are one of the richest sources of
potentially new bioactive compounds in the world. It is estimated that they contain up to 106
to 109 microbial cells per millilitre of water. As previously mentioned, microbial communities
inhabiting marine environments are usually exposed to extreme conditions such as low or high
temperatures (0 to 100 ˝C), high pressures (up to 100 MPa) and low nutrient availability. Their
adaption to a broad variety of conditions led to the development of different survival strategies
and unique biochemical, metabolic and physiological features, stemming from their wide microbial
diversity. Furthermore, as the environmental conditions of marine ecosystems are very different from
terrestrial ones, it is expected that marine microorganisms produce compounds with new properties
and biological activities comparing to those produced by microbes of terrestrial origin [26,85–87].
In the last years, there has been an increasing interest in the study and exploration of marine
microorganisms as a source of new compounds for application in different fields. For instance, several
biosurfactants with pharmaceutical and medical relevance have been obtained from microorganisms
isolated from marine environments, as mentioned in the sections above. However, the recent
use of molecular techniques to study the diversity of marine ecosystems revealed that most of
the marine microbial world remains unexplored, particularly due to the difficult of growing most
of those microorganisms under laboratory conditions [26,85,86]. Culture-independent techniques
(metagenomics) are a promising way to study the genetic resources of otherwise inaccessible marine
microorganisms, and discover previously unknown natural compounds with important biological
activities, without the requirement of culturing them. Metagenomics is a collection of molecular
techniques that allow the culture-independent study of microbial communities from any environmental
sample through the direct extraction and study of their genetic material, giving access to the total
genetic pool and biosynthetic capacity of all the microorganisms present in that community [86,88].
Metagenomic studies usually start with the extraction of the DNA from the environmental sample
under study (in the case of marine ecosystems, it can be seawater, marine sediments or marine
macro-organisms), although they can be based also on RNA. The DNA sample must represent (both
qualitatively and quantitatively) all the microbial species present in the community. The next step is
the construction of metagenomic libraries, using suitable cloning vectors. Different vectors can be used,
depending on the size of the DNA fragments obtained: plasmids (which can incorporate DNA inserts
up to 15 kb); cosmids and fosmids (between 15 and 45 kb); and bacterial artificial chromosomes (up to
100–200 kb). Subsequently, the metagenomic library is transferred to a suitable host strain, usually
E. coli. Finally, the individual recombinant clones are screened. The screening process can be based
on the sequences of the DNA inserts cloned (sequence-based metagenomics), or in the functions that
those DNA inserts confer to the host (function-based metagenomics) [85,87,88].
The sequence-based metagenomics can be performed through large-scale random sequencing of
metagenomic libraries, which generates a high amount of sequences. Those sequences are subsequently
analysed using bioinformatics tools and are compared with sequences deposited in the databases
through homology-based searches. Some of those sequences can correspond to novel genes with
unknown functions. The development of next-generation sequencing technologies in recent years, as
well as the subsequent significant reduction of DNA sequencing costs led to considerable progress
in sequence-based metagenomics, allowing its widespread use. On the other hand, sequence-based
metagenomics can be performed based on the sequence similarity, using Polymerase Chain Reaction
(PCR) or DNA hybridization techniques. In this case, once selected the target genes (or proteins),
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PCR primers or DNA probes are designed according to consensus sequences specific to the most
conserved regions of those genes (or proteins), and these are further used to screen the metagenomic
library. The main drawback of this approach is that it requires a previous knowledge of the sequences
of the genes, which naturally limits the discovery of new functions or activities [26,85]. For instance,
in the specific case of biosurfactants, this approach can be used to search for new genes involved in
their biosynthesis based on the sequences of already known genes. As a result, the new biosurfactants
found are expected to be similar to those previously reported. However, in some cases, those genes can
show slight modifications that can lead to the production of biosurfactants with different properties
and activities.
On the contrary, function-based metagenomics consists in screening metagenomic libraries
for the presence of activities or phenotypes resulting from the heterologous expression of the
genes present in the microbial community. The main advantage of this approach is that it is not
dependent on the previous knowledge of the DNA sequences; consequently, it is the best way
to identify new genes and gene families encoding novel biomolecules that could not be detected
using the sequence-based approaches from comparisons with previously described genes. However,
function-based metagenomics entails several difficulties and challenges. Its success is dependent on
the expression of the foreign genes in the heterologous host used. The most common host used for
the construction of metagenomic libraries is E. coli. However, it does not guarantee the expression of
all the genes existent in the microbial community under study, due to problems associated with the
recognition of promoters from different taxonomic groups by the transcriptional machinery of E. coli,
or differences in the codon usage preferences. Some examples of functional screening of metagenomic
libraries for new antimicrobial compounds using E. coli and other alternative hosts simultaneously
(Bacillus subtilis, Ralstonia metallidurans or Streptomyces lividans) resulted in the detection of antimicrobial
activities in the alternative hosts, but not in E. coli [89–91]. For that reason, there is a growing tendency
to use various hosts simultaneously with the objective of expressing most of the genes present in the
microbial community. In this case, the use of broad-host range vectors is necessary to construct the
metagenomic libraries. Furthermore, if a function is encoded by several genes grouped in one operon,
only if the complete operon is cloned in a single DNA insert could it be detected. For instance, the
genes involved in the biosynthesis of lipopeptide biosurfactants (e.g., surfactin, lichenysin, fengycin
or iturin), are grouped in operons ranging from 25 to 40 kb in size [92]. This means that the vectors
used to construct the metagenomic libraries to identify new biosurfactants must be able to incorporate
DNA inserts larger than 20 to 30 kb. Another problem is that, even if the corresponding gene is
correctly expressed, if the resulting product is not excreted, it would not be detected during the
screening processes. These difficulties are not applicable to the sequence-based metagenomics, where
the expression of the DNA inserts is not necessary.
Furthermore, function-based metagenomics requires the development of adequate screening
methods that must be sensitive and, at the same time, applicable to thousands of transformants,
as metagenomic libraries with sufficient coverage of the whole community require an extremely large
number of clones. It can be performed by heterologous complementation of host strains or mutants
by target genes to allow their growth under selective conditions, or to allow the use of a specific
substrate; or using chromogenic or fluorescent substrates to detect specific enzymatic activities [85–87].
For the identification of new antimicrobial compounds, it can be performed by screening clones for
antimicrobial activity against clinically relevant microorganisms.
Despite all these issues, there are several examples of new bioactive compounds (mainly
enzymes) obtained from marine samples through the application of function-based metagenomics
(as reviewed by Felczykowska et al. [85] and Kennedy et al. [86]). Also, new antimicrobials have been
discovered through functional screening of soil metagenomic libraries (as reviewed by Coughlan
and co-workers [88]). However, to date there are no reports on the discovery of new biosurfactants
using function-based metagenomics, which can be due to the difficulty of establishing an appropriate
screening method. Measuring the surface tension or the emulsifying activity is not feasible to screen
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thousands of transformants. Other techniques commonly used to screen biosurfactant-producing
microorganisms, such as oil spreading or the drop collapse assays, can show poor efficiency when
applied on a large scale. Furthermore, all these techniques require growing the transformants in liquid
medium to evaluate the production of biosurfactants. Several colorimetric techniques can be applied
to detect biosurfactants on agar plates, but they are directed to specific biosurfactants, thus they are not
useful to identify new compounds. One of these methods uses bromothymol blue (colour indicator)
and cetylpyridinium chloride (mediator), which change from yellow-green to dark green or bright
blue in the presence of different concentrations of surfactin; it has been successfully used to identify
surfactin-hyperproducing B. subtilis strains [93]. The cetyltrimethylammonium bromide (CTAB) agar
plate method is a semi-quantitative assay for the detection of extracellular anionic biosurfactants.
In this case, the potential biosurfactant-producing clones are grown in agar plates containing the
cationic surfactant CTAB and the basic dye methylene blue. Biosurfactant-producing colonies are
surrounded by dark blue halos due to the formation of an insoluble ion pair between the anionic
biosurfactant, CTAB and methylene blue [94]. However, it is not clear if these techniques can be
useful to identify new biosurfactants. A more interesting option could be the atomized oil assay
described by Burch et al. [95], which can be applied directly on agar plates. It consists in applying a
fine mist of oil droplets onto the plate (where the transformants have been grown previously) using
an airbrush. Biosurfactant production can be detected instantaneously due to the formation of halos
around biosurfactant-producing colonies. This technique can detect low concentrations of different
chemical surfactants and biosurfactants (including glycolipids and lipopeptides) and is more sensitive
than the drop collapse assay [95], thus it could be a good method to screen metagenomic libraries for
novel biosurfactants.
5. Conclusions
In recent years, there has been an increasing interest in the study and exploration of marine
microorganisms as potential producers of new compounds for application in different areas, as the
marine environment represents a promising source of novel bioactive compounds. Biosurfactants of
marine origin, although less explored than their terrestrial counterparts, exhibit some properties that
make them useful and powerful for several therapeutic applications, as alternatives to the existing
drugs. However, the difficulty of isolating and growing these marine microorganisms means that most
of the marine microbial world remains unexplored. Function-based metagenomics, while exhibiting
several limitations, constitutes a promising approach to study the genetic resources of otherwise
inaccessible marine microorganisms, giving access to the total genetic pool and biosynthetic capacity
of all the microorganisms in a community, as well as allowing the discovery of novel biosurfactants.
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